MedTrace Logo

HIV, Buprenorphine, and the Criminal Justice System (STRIDE2)

NCT03583138 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 159

Last updated 2020-05-27

No results posted yet for this study

Summary

STRIDE2 is a longitudinal, non-randomized study of individuals living with HIV who are dependent on opioids. This study is funded by the National Institute on Drug Abuse (R01DA030768, Altice, PI; Taxman \& Lawson, Co-PIs) and is being conducted by George Mason University, Yale University, and Howard University.

Conditions

  • Human Immunodeficiency Virus
  • Acquired Immunodeficiency Syndrome
  • Opiate Addiction
  • Drug Dependence

Interventions

DRUG

buprenorphine

To provide buprenorphine for 12 months for those who are interested in receiving it.

Sponsors & Collaborators

  • National Institute on Drug Abuse (NIDA)

    collaborator NIH

  • George Mason University

    collaborator OTHER

  • Howard University

    collaborator OTHER

  • Yale University

    lead OTHER

Principal Investigators

  • Fredrick Altice, MD · Yale University School of Medicine/AIDS Program

  • Faye Taxman, PhD · George Mason University

  • William Lawson, MD · Howard University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-06-23
Primary Completion
2015-12-15
Completion
2017-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03583138 on ClinicalTrials.gov